Stocks and Investing
Stocks and Investing
Fri, March 26, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Thomas Shrader Maintained (BCAB) at Strong Buy with Increased Target to $87 on, Mar 26th, 2021
Thomas Shrader of BTIG, Maintained "BioAtla, Inc." (BCAB) at Strong Buy with Increased Target from $47 to $87 on, Mar 26th, 2021.
Thomas has made no other calls on BCAB in the last 4 months.
There are 3 other peers that have a rating on BCAB. Out of the 3 peers that are also analyzing BCAB, 0 agree with Thomas's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Thomas
- Anupam Rama of "JP Morgan" Initiated at Buy and Held Target at $45 on, Monday, January 11th, 2021
- Biren Amin of "Jefferies" Initiated at Strong Buy and Held Target at $51 on, Monday, January 11th, 2021
- Tiago Fauth of "Credit Suisse" Initiated at Buy and Held Target at $49 on, Monday, January 11th, 2021
Contributing Sources